| 產(chǎn)品編號 | bs-1281R-Cy5.5 |
| 英文名稱 | Rabbit Anti-XIAP/BIRC4/Cy5.5 Conjugated antibody |
| 中文名稱 | Cy5.5標記的X-連鎖凋亡蛋白/性連鎖凋亡抑制蛋白抗體 |
| 別 名 | X-linked Inhibitor of Apoptosis Protein; RIAP-3; Baculoviral IAP repeat-containing protein 4; E3 ubiquitin-protein ligase XIAP; Inhibitor of apoptosis protein 3; X-linked IAP; IAP-like protein; HILP; BIRC4; HILP; XLP2; ILP1; Xiap; MIHA; hILP; IAP3; API3; XIAP; XIAP_HUMAN; ILP; hILP; IAP-3; hIAP-3; hIAP3; X-linked inhibitor of apoptosis protein. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 免疫學 細胞凋亡 轉錄調(diào)節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, Rat, |
| 產(chǎn)品應用 | Flow-Cyt=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 55kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human XIAP |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a protein that belongs to a family of apoptotic suppressor proteins. Members of this family share a conserved motif termed, baculovirus IAP repeat, which is necessary for their anti-apoptotic function. This protein functions through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2 and inhibits apoptosis induced by menadione, a potent inducer of free radicals, and interleukin 1-beta converting enzyme. This protein also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. Mutations in this gene are the cause of X-linked lymphoproliferative syndrome. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene are found on chromosomes 2 and 11.[provided by RefSeq, Feb 2011] Function: Apoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B. Subunit: Monomer, and homodimer. Interacts with SMAC and with PRSS25; these interactions inhibit apoptotic suppressor activity. Interacts with MAP3K7IP1 and AIFM1. Interaction with SMAC hinders binding of MAP3K7IP1 and AIFM1. Interacts with TCF25. Subcellular Location: Cytoplasm. Tissue Specificity: Ubiquitous, except peripheral blood leukocytes. Post-translational modifications: Ubiquitinated and degraded by the proteasome in apoptotic cells. Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation. DISEASE: Defects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma. Similarity: Belongs to the IAP family. Contains 3 BIR repeats. Contains 1 RING-type zinc finger. Database links: Entrez Gene: 331 Human Entrez Gene: 11798 Mouse Omim: 300079 Human SwissProt: P98170 Human SwissProt: Q60989 Mouse Unigene: 356076 Human Unigene: 259879 Mouse Unigene: 91239 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. X-連鎖凋亡蛋白是凋亡抑制蛋白家族中作用最強、功能最全面的caspase抑制因子,發(fā)揮著抗凋亡作用。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
